Nothing Special   »   [go: up one dir, main page]

PL3831385T3 - Sole migdalanowe enancjomerów pirlindolu do stosowania w medycynie - Google Patents

Sole migdalanowe enancjomerów pirlindolu do stosowania w medycynie

Info

Publication number
PL3831385T3
PL3831385T3 PL20198230.3T PL20198230T PL3831385T3 PL 3831385 T3 PL3831385 T3 PL 3831385T3 PL 20198230 T PL20198230 T PL 20198230T PL 3831385 T3 PL3831385 T3 PL 3831385T3
Authority
PL
Poland
Prior art keywords
medicine
mandelate salts
pirlindole enantiomers
pirlindole
enantiomers
Prior art date
Application number
PL20198230.3T
Other languages
English (en)
Inventor
Augusto Eugénio PARDAL FILIPE
Pedro Filipe EUFRÁSIO PEDROSO
Susana Marques ALMEIDA PECORELLI
Carlos Alberto Casimiro Caixado
Ana Sofia da Conceição LOPES
João Carlos Ramos DAMIL
Pedro Paulo de Lacerda E OLIVEIRA SANTOS
Ana Lúcia ALMEIDA FERREIRA
Original Assignee
Tecnimede Sociedade Tecnico-Medicinal S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico-Medicinal S.A. filed Critical Tecnimede Sociedade Tecnico-Medicinal S.A.
Publication of PL3831385T3 publication Critical patent/PL3831385T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL20198230.3T 2014-05-09 2014-05-09 Sole migdalanowe enancjomerów pirlindolu do stosowania w medycynie PL3831385T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/PT2014/000026 WO2015171002A1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
EP20198230.3A EP3831385B1 (en) 2014-05-09 2014-05-09 Mandelate salts of pirlindole enantiomers for use in medicine

Publications (1)

Publication Number Publication Date
PL3831385T3 true PL3831385T3 (pl) 2024-10-14

Family

ID=50819928

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20198230.3T PL3831385T3 (pl) 2014-05-09 2014-05-09 Sole migdalanowe enancjomerów pirlindolu do stosowania w medycynie

Country Status (24)

Country Link
US (1) US10226460B2 (pl)
EP (2) EP3831385B1 (pl)
JP (1) JP6400121B2 (pl)
KR (1) KR102276281B1 (pl)
CN (1) CN106413713B (pl)
AU (1) AU2014393487B2 (pl)
CA (1) CA2948595C (pl)
DK (1) DK3831385T3 (pl)
EC (1) ECSP16086196A (pl)
FI (1) FI3831385T3 (pl)
IL (1) IL248852B (pl)
LT (1) LT3831385T (pl)
MA (1) MA39450B2 (pl)
MX (1) MX2016014704A (pl)
NZ (1) NZ726127A (pl)
PH (1) PH12016502235A1 (pl)
PL (1) PL3831385T3 (pl)
PT (1) PT3831385T (pl)
RS (1) RS65918B1 (pl)
RU (1) RU2706688C2 (pl)
SA (1) SA516380258B1 (pl)
TN (1) TN2016000495A1 (pl)
UA (1) UA118587C2 (pl)
WO (1) WO2015171002A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368734B (es) * 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
PT3054950T (pt) 2014-05-09 2017-11-29 Tecnimede-Sociedade Tecnico-Medicinal S A (r)-pirlindol ou seus sais farmaceuticamente aceitáveis para uso em medicina
EP3392250A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of piperazine ring for the synthesis of pyrazinocarbazole derivatives
EP3392251A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of pirlindole enantiomers and its salts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO166131C (no) * 1985-06-20 1991-06-05 Daiichi Seiyaku Co Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser.
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
BRPI0922871A2 (pt) * 2008-12-11 2016-11-16 Biovista Inc metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
WO2014062621A1 (en) * 2012-10-15 2014-04-24 Stc.Unm Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
MX368734B (es) * 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
PT3054950T (pt) * 2014-05-09 2017-11-29 Tecnimede-Sociedade Tecnico-Medicinal S A (r)-pirlindol ou seus sais farmaceuticamente aceitáveis para uso em medicina
EP3140265B1 (en) * 2014-05-09 2019-08-28 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for obtaining optically active pirlindole enantiomers and salts thereof

Also Published As

Publication number Publication date
PH12016502235A1 (en) 2017-01-09
CN106413713A (zh) 2017-02-15
EP3831385A1 (en) 2021-06-09
EP3831385B1 (en) 2024-07-10
MA39450B2 (fr) 2021-10-29
CA2948595C (en) 2021-07-13
CA2948595A1 (en) 2015-11-12
CN106413713B (zh) 2020-07-14
DK3831385T3 (da) 2024-08-26
TN2016000495A1 (en) 2018-04-04
WO2015171002A1 (en) 2015-11-12
RS65918B1 (sr) 2024-10-31
JP2017514882A (ja) 2017-06-08
ECSP16086196A (es) 2017-02-24
IL248852B (en) 2020-05-31
SA516380258B1 (ar) 2019-11-04
FI3831385T3 (fi) 2024-09-04
LT3831385T (lt) 2024-09-10
JP6400121B2 (ja) 2018-10-03
RU2706688C2 (ru) 2019-11-20
MX2016014704A (es) 2017-05-23
AU2014393487B2 (en) 2020-01-02
AU2014393487A1 (en) 2016-11-24
US20170143710A1 (en) 2017-05-25
RU2016148174A3 (pl) 2018-06-14
PT3831385T (pt) 2024-09-24
NZ726127A (en) 2019-03-29
RU2016148174A (ru) 2018-06-14
KR102276281B1 (ko) 2021-07-13
UA118587C2 (uk) 2019-02-11
IL248852A0 (en) 2017-01-31
KR20170002433A (ko) 2017-01-06
EP3139926A1 (en) 2017-03-15
MA39450A1 (fr) 2017-08-31
US10226460B2 (en) 2019-03-12

Similar Documents

Publication Publication Date Title
HK1231474A1 (zh) 磷脂酰肌醇 -激酶抑制劑
HK1231477A1 (zh) 磷脂酰肌醇 -激酶抑制劑
SI3125883T1 (sl) Indol derivati za uporabo v medicini
IL252873A0 (en) The l-tartrate salt of pridopidine
IL247072A0 (en) Medical use
HK1231476A1 (zh) 磷脂酰肌醇 -激酶抑制劑
IL251988A0 (en) Compounds acting on glycans and methods of using them
IL249079A0 (en) Phosphatidylinositol 3-kinase inhibitors
IL248789A0 (en) History of quinazolinones as phosphatidylinositol 3-kinase inhibitors
SG11201609540TA (en) Phosphatidylinositol 3-kinase inhibitors
SI3089971T1 (sl) Spojine in postopki za uporabo
ZA201606450B (en) Compounds and their methods of use
IL248852A0 (en) Pharmaceutically acceptable salts of pyrilindole enantiomers for use in medicine
ZA201607722B (en) Process for obtaining optically active pirlindole enantiomers and salts thereof
GB201608510D0 (en) Apparatus for clinical use
IL235340A (en) One-time vase
GB201403697D0 (en) Compounds and methods of use
TH1601006735A (th) เกลือที่ยอมรับได้ทางเภสัชกรรมของเพอร์ลินโดลอีแนนทิโอเมอร์สำหรับ การใช้ในยารักษาโรค
GB201408594D0 (en) New salts